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Purpose: Mucopolysaccharidosis II (MPS II) is a lysosomal storage disorder 
caused by a deficiency of iduronate-2 sulfatase (IdS), which is involved in the deg-
radation of glycosaminoglycan (GAG). In this study, the frequency of fasting hy-
poglycemia in patients with MPS II was investigated and changes in accumulation 
of glycogen and GAG in the hepatocytes of IdS-knockout (KO) mice were evalu-
ated before and after recombinant IdS enzyme replacement therapy (ERT). Mate-
rials and Methods: Plasma glucose levels were evaluated after an 8-hour fast in 
50 patients with MPS II. The IdS-KO mice were divided into three groups (group 
2; saline, group 3; 0.15 mg/kg of IdS, and group 4; 0.5 mg/kg of IdS); wild-type 
mice were included as controls (group 1). ERT was initiated intravenously at four 
weeks of age, and continued every week until 20 weeks of age. Results: The mean 
glucose level after an 8-hour fast was 94.1 ± 23.7 mg/dL in the patients with MPS 
II. Two (4%) out of 50 patients had fasting hypoglycemia. For the mice, GAG in 
the lysosomes nearly disappeared and glycogen particles in the cytoplasm were re-
stored to the normal range in group 4. Conclusion: Glucose metabolism in patients 
with MPS II appeared to function well despite hepatocytic GAG accumulation and 
hypothetical glycogen depletion. A higher dose of IdS infusion in MPS II mice led 
to disappearance of lysosomal GAG and restoration of glycogen to the cytoplasm 
of hepatocytes. 
Key Words:    Mucopolysaccharidosis II, iduronate-2-sulfatase knockout mice, glyco-
gen, glycosaminoglycan, idursulfase supplementation, liver histology
INTRODUCTION
Mucopolysaccharidosis II (MPS II, Hunter syndrome) is a lysosomal storage dis-
order; it is caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase 
(IdS), which is involved in the degradation of glycosaminoglycan (GAG).1 MPS II 
is an X-linked recessive disorder and occurs predominantly in males. The accumu-
lation of GAG in tissues and organs is responsible for the associated clinical ab-
normalities.1 The liver is the primary site of accumulation of GAG; as a result, Jee Hyun Lee, et al.
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10 IdS-KO mice without ERT. In group 3 there were four 
IdS-KO mice treated with 0.15 mg/kg of IdS, and in group 
4, three IdS-KO mice treated by a 0.5 mg/kg IdS infusion.
Enzyme replacement therapy
The recombinant IdS enzymes used in this study were rem-
nants of idursulfase (Elaprase®, Shire, Cambridge MA, 
USA) used for patient treatment. The remnants were used 
after informed consent was obtained from the parents of the 
patients. Recombinant IdS was injected into the lateral tail 
vein of mice in groups 3 and 4. ERT was initiated at 4 weeks 
of age, and continued every week until 20 weeks of age. 
Pathology examinations for GAG and glycogen
At approximately 20 weeks of age, the mice were sacrificed 
and a comprehensive necropsy was performed. The livers 
were dissected and fixed in formalin, and made in paraffin 
block for light microscopic examinataion. The 4-6 μm thick-
ness sections were put on glass slides and stained with peri-
odic acid-Schiff (PAS) and digested periodic acid-Schiff (d-
PAS), which stains tissue glycogen, and colloidal iron, 
which stains for excessive GAG. A routine pathology ex-
amination was performed in a blind manner by the patholo-
gist. Under the light microscopic (LM) examination, semi-
quantitative verification of the GAG content of Kupffer cells 
was performed, scoring from absent (0) to global (2) and for 
the glycogen content of liver tissue, ranging from scanty 
(0.5) to global (3). The specimens were examined three 
times by the same pathologist.
Measurements of glycogen weights
The glycogen content of liver tissue was measured indirect-
ly using amyloglucosidase digestion of the homogenates of 
liver tissue and weighing the amount of glucose present. 
 
Electron microscopic examination
For the electron microscopic (EM) examination, the tissue 
was fixed in 2.5% glutaraldehyde solution, postfixed in 1.5% 
osmium tetroxide solution, dehydrated, and fixed firmly into 
polybed resin. Microthin section and staining with lead ci-
trate and uranyl acetated were done. A comparison of the 
changes in the liver tissue before and after ERT was per-
formed by EM examination.
 
Statistical analysis
A comparison of GAG and glycogen among the groups 
was analyzed by the Kruskal-Wallis test. To verify differenc-
hepatomegaly is an invariable finding in patients with this 
disorder.1 Enzyme replacement therapy (ERT) with recom-
binant human IdS has been reported to be effective for the 
treatment of MPS II.2-5 An IdS-knockout (KO) mouse mod-
el was constructed to study the effects of ERT on mice with 
MPS II.
Recently, a patient with MPS II and hypoglycemia was 
treated; the patient had palpitations, was irritable, and had 
increased sweating and episodes of syncope. The reduced 
amount of glycogen in the hepatocytes was thought to cause 
accumulation of GAG, which might have been responsible 
for the observed hypoglycemia. This could be explained by 
the findings of our pilot study, where the liver pathology of 
IdS-KO mice showed a decreased amount of glycogen in 
the hepatocytes. To confirm these findings, the frequency of 
fasting hypoglycemia in patients with MPS II was investi-
gated. In addition, changes in accumulation of glycogen 
and GAG in the hepatocytes of IdS-KO mice before and af-
ter recombinant IdS infusion was evaluated.
 
MATERIALS AND METHODS
Hypoglycemia after an 8-hour fast in patients with MPS II 
Plasma glucose levels in 50 patients with MPS II were evalu-
ated. Hypoglycemia was defined as a plasma glucose con-
centration of less than 55 mg/dL.6 The measurements were 
performed at 8 a.m. after an 8-hour fast. Glucose levels 
were also measured 2 hours after a meal.
IDS knockout mice
A KO mouse model was developed by Jin, DK, MD (De-
partment of Pediatrics, Samsung Medical Center, Sung-
kyunkwan University School of Medicine, Seoul, Korea) 
and was reported previously.7 Briefly, a murine model of 
Hunter syndrome was prepared by replacing part of the IdS 
gene, exon 2 and exon 3, with the neomycin resistance 
gene. Carrier females were bred with male mice with a   
B6/129 background strain, producing heterogeneous fe-
males and hemizygous male knock-out mice, as well as 
wild-type (WT) male and female littermates. The genotype 
of all mice used in these experiments was confirmed by 
polymerase chain reaction of DNA obtained from a tail snip.   
Grouping
The animals were categorized into four groups. Eight nor-
mal mice were included in group 1. Group 2 consisted of Hepatic Glycogen and GAG in IdS-Knockout Mice
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with ERT (Table 1). 
The glycogen content in the cytoplasm of hepatocytes, in 
the liver tissue of the mice, also differed among the four 
groups based on the findings of the semiquantitation period-
ic acid Schiff positive findings; the findings showed   sensi-
tivity to diastase digestion (p = 0.005). Group 1 had a higher 
concentration of glycogen than groups 2 and 3. Comparison 
between the two treated groups showed that the group with 
a higher dose of enzyme infusion had higher glycogen con-
tent than the group with a lower dose of enzyme infusion by 
the LSD (Table 2). 
Glycogen weights 
The fresh liver tissue from the mice was analyzed to deter-
mine glycogen content, and compared with the results of 
the semiquantitation pathology. There were significant dif-
ferences in glycogen content among the four groups (p = 
0.009)(Table 2). The mean glycogen content of group 1 
was 5.75 ± 1.43 wet weight (%), which was more than 
those of group 2 [2.80 ± 1.07 wet weight (%)] and group 3 
[2.80 ± 2.18 wet weight (%)]. The glycogen content for 
group 4 was 5.27 ± 1.92 wet weight (%). The glycogen wet 
weights were positively correlated with the results of the 
histological semiquantitation (p = 0.001, Spearman correla-
tion coefficient = 0.74349)
Electron microscopic examination
The ultrastructural findings observed on electron microsco-
py were consistent with the light microscopy findings for 
es among groups, the results were reanalyzed using least sig-
nificant difference (LSD) using ranks. Glycogen wet weight 
and histological semiquantitation were analyzed using the 
Spearman rank correlation coefficient. 
RESULTS
Hypoglycemia after an 8-hour fast in MPS II patients
The mean glucose level after an 8-hour fast was 94.1 ± 23.7 
mg/dL. Two (4%) out of 50 patients had fasting hypoglyce-
mia. The mean plasma glucose level 2 hours after a meal 
was 110.9 ± 17.8 mg/dL. The levels were within normal 
range in all patients.
Pathological findings in the murine model
Upon routine histological examination, there was no signif-
icant difference in architecture or inflammatory changes be-
fore and after ERT. However, there were changes in GAG 
and glycogen content. GAG accumulation in liver tissues 
was compared among the groups, based on semiquantita-
tion of colloidal iron staining. There were significant differ-
ences in the GAG assay among the groups (p = 0.015). 
Group 2 had a higher concentration of GAG compared to 
the other three groups, based on positive iron colloidal stain-
ing. Reduction of GAG content in the treated mice of groups 
3 and 4 reflected the effects of ERT. However, there was no 
difference between groups 3 and 4 based on the dose of en-
zyme infusion or between group 1 and the groups treated 
Table 1.  GAG Comparisons between Groups Using the Kruskal-Wallis Test 
Group Mean ± SD Chi-square df p value
Semiquantitation of GAG 
by grade (0 - 2) 
Group 1 (n = 8) 0.6250 ± 0.5175 10.4965 3 0.015
  Group 2 (n = 10) 1.4000 ± 0.6325
Group 3 (n = 4) 0.5000 ± 0.5774
Group 4 (n = 3) 0.6667 ± 0.5774
GAG, glycosaminoglycan; df, degree of freedom.
Table 2. Glycogen Comparisons between Groups Using the Kruskal-Wallis Test 
Group Mean ± SD Chi-square df p value
Semiquantitation of 
  glycogen by grade (0.5 - 3)
Group 1 (n = 8) 2.0000 ± 0.0000 13.0276 3 0.005
  Group 2 (n = 10) 1.3000 ± 0.7149
Group 3 (n = 4) 0.8750 ± 0.4787
Group 4 (n = 3) 1.8333 ± 0.2887
Quantitation of glycogen 
  (%wet weight)
Group 1 (n = 8) 5.7500 ± 1.4373 11.6908 3 0.009
  Group 2 (n = 10) 2.8000 ± 1.0739
Group 3 (n = 4) 2.8000 ± 2.1833
Group 4 (n = 3) 5.2667 ± 1.9296
df, degree of freedom.Jee Hyun Lee, et al.
Yonsei Med J   http://www.eymj.org   Volume 52   Number 2   March 2011 266
patients with MPS II would have hepatic glycogen deple-
tion contributing to fasting hypoglycemia. Instead, these 
findings suggest that glucose metabolism, including hepatic 
glycogen synthesis and gluconeogenesis, were functioning 
well despite GAG accumulation and hypothetical glycogen 
depletion in the MPS II hepatocytes. 
The findings from the murine model showed that GAG 
decreased in both the low and high dose ERT groups; how-
ever, glycogen was restored to normal range only in the 
high dose ERT group, which implies that high dose ERT is 
required to achieve the desired response. This result is con-
sistent with the findings reported by Garcia, et al.,5 where 
urine GAG levels deceased in a dose-dependent manner. 
The reason why GAG semiquantitation assay results in this 
study did not show a significant difference between groups 
3 and 4 might be due to the small number of samples in the 
two groups. 
iron colloidal, PAS and d-PAS stains with regards to GAG 
and glycogen content. Group 2 showed accumulation of 
GAG in the lysosomes and scanty glycogen content in the 
cytoplasm. In group 3, the GAG in the lysosomes decreased, 
but restoration of glycogen in the cytoplasm was not re-
markable. However, in group 4, GAG in the lysosomes had 
nearly disappeared and the glycogen particles in the cyto-
plasm were restored (Fig. 1).
DISCUSSION
Most of the patients with MPS II did not have hypoglyce-
mia after an 8-hour fast. Even though two patients had fast-
ing hypoglycemia, and one of them showed hypoglycemic 
symptoms, the fasting glucose levels in most patients were 





Fig. 1. High power electron microscopic findings (9.0 × 9,000). (A) Wild type: the arrow shows large amounts of glycogen particles in the 
cytoplasm. (B) MPS II model: the arrow shows accumulation of GAG in lysosomes and scanty glycogen content in the cytoplasm. (C) Low 
dose ERT group: GAG in the lysosomes decreases but restoration of glycogen in the cytoplasm is not remarkable. (D) High dose ERT 
group: GAG in the lysosomes nearly disappears and glycogen particles in the cytoplasm are restored. MPS II, mucopolysaccharidosis II; 
GAG, glycosaminoglycan; ERT, enzyme replacement therapy.Hepatic Glycogen and GAG in IdS-Knockout Mice
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ERT. Therefore, these findings suggest that ERT can be an 
effective treatment and should be started as early as possi-
ble during childhood.
In conclusion, high dose ERT in MPS II mice led to 
marked disappearance of lysosomal GAG and restoration 
of normal levels of glycogen in the cytoplasm of the hepa-
tocytes. Normal accumulation of glycogen in hepatocytes is 
disturbed by the metabolites produced in this storage dis-
ease; however, this process is reversible. 
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Resnick, et al.8 reported that the histological findings of 
liver biopsy samples from 27 MPS cases showed no archi-
tectural changes, inflammatory infiltrates, or extensive fi-
brosis. The results of this study also showed no specific his-
tological changes in liver tissue, except for glycogen content 
depletion and GAG accumulation in the MPS II murine 
model. 
The results of this study suggest that ERT in MPS II mice 
may influence hepatocyte glycogen content as well as lyso-
somal GAG. However, there is no known relationship be-
tween the regulation of synthesis, storage, and degradation 
of glycogen and the lysosomal accumulation and degrada-
tion of GAG in the liver. Therefore, the mechanism by which 
the amount of glycogen in the cytoplasm appears to be in-
versely proportional to the lysosomal GAG, based on the 
amount of enzyme supplementation, remains unclear. Two 
possible mechanisms have been proposed: 1) MPS II is as-
sociated with GAG accumulation in the lysosomes, result-
ing in lysosomal expansion. As GAG accumulates, space 
for normal glycogen in the cytoplasm is reduced. By con-
trast, after ERT, lysosomal GAG disappears and glycogen 
in the cytoplasm is built up to the level of normal hepato-
cytes. 2) Certain metabolites produced in MPS II may block 
the glycogen synthesis pathway, leading to glycogen deple-
tion. After ERT, the metabolites may disappear, restoring 
normal glucose metabolism, which mediates stimulation of 
insulin release and glycogen synthesis. 
Further studies linking hepatic metabolites produced in 
MPS II with glycogen metabolism may lead to better un-
derstanding of the mechanisms involved in hepatocyte gly-
cogen depletion. The murine model did not provide evidence 
of hepatic fibrosis or cirrhosis. This finding is consistent with 
the results of Resnick, et al.,8 who reported fibrotic changes 
in liver biopsy samples from 27 infant MPS cases. Hepatic 
fibrosis in patients with MPS has been reported in the liter-
ature, mainly in adult cases.9,10 Parfrey and Hutchins sug-
gested that hepatic fibrosis is due to abnormal accumulation 
of hepatotoxic metabolites.9 The MPS II murine model in 
this study showed that liver damage was not significant; ly-
sosomal accumulation of GAG and histological changes 
during were observed in the early stages, but no fibrosis. 
Furthermore, histological changes returned to normal after 